Diagnosing persistent corneal epithelial defects requires careful examination and specialized testing to identify both the defect itself and the underlying causes that prevent normal healing. Understanding when to seek diagnostic evaluation and what tests may be performed is essential for patients experiencing ongoing eye symptoms that don’t improve with time.

Introduction: Who Should Undergo Diagnostics

Anyone experiencing ongoing eye pain, discomfort, or visual changes should consider seeking diagnostic evaluation, especially when symptoms persist beyond a week or two of standard treatment. People who should be particularly vigilant about getting diagnosed include those who have recently suffered eye injuries, individuals with chronic dry eye disease, people with diabetes, and anyone who has undergone eye surgery in the past.^[1]

The diagnosis becomes especially important when symptoms appear repeatedly or fail to resolve with typical supportive care. If you find yourself waking up with sudden eye pain, experiencing a sensation that something is stuck in your eye, or noticing that your vision becomes blurry and doesn’t clear, these are signs that warrant a thorough diagnostic examination. Patients with autoimmune diseases, those who wear contact lenses regularly, or individuals who have previously been diagnosed with corneal conditions should seek evaluation promptly when new or recurring symptoms develop.^[2]

It’s advisable to seek diagnostics within seven to ten days of experiencing persistent symptoms to avoid secondary complications that can develop when the cornea remains unhealed for extended periods.^[2] Early intervention not only helps identify the problem but also prevents potentially serious consequences such as infection, scarring, or even vision loss. People who have risk factors like previous eye trauma, corneal surgery such as LASIK or cataract procedures, or conditions affecting the eyelids should be especially proactive about seeking diagnostic care when they notice eye surface problems.^[4]

Diagnostic Methods

Initial Clinical Examination

The diagnosis of persistent corneal epithelial defects begins with a thorough clinical history and physical examination of the eye. Your eye doctor will ask detailed questions about when your symptoms started, whether you’ve had any recent eye injuries or surgeries, what medications you’re taking, and whether you have any underlying medical conditions such as diabetes or autoimmune diseases. This information helps identify potential causes and risk factors that may be contributing to the problem.^[4]

Before applying any drops or dyes, the doctor will assess your corneal sensation—this means checking whether you can feel light touches on the surface of your eye. Reduced sensation can indicate nerve damage that prevents proper healing. The examination also includes evaluating your eyelid structure and how well your eyelids close, as incomplete closure can expose the cornea and prevent healing. The doctor will look for signs of inflammation, scarring, or abnormal tissue growth on the surface of the eye and surrounding structures.^[4]

Fluorescein Staining

The most important diagnostic tool for visualizing persistent epithelial defects is fluorescein staining, which uses a special orange dye combined with blue light. When fluorescein dye is applied to the eye’s surface, it highlights areas where the protective epithelial layer is missing or damaged. Under blue light, these damaged areas glow bright green, allowing the doctor to see exactly where the defect is located, how large it is, and what shape it has.^[3]

The timing of this examination is crucial. The defect appears most clearly immediately after the fluorescein is applied, so doctors typically measure and photograph the affected area right away. If they wait even a few minutes, the dye can spread into surrounding tissue and the underlying layers of the cornea, making the edges of the defect harder to identify accurately. This immediate documentation also allows the doctor to track changes in size and healing progress at future visits.^[10]

Additional Dye Testing

In addition to fluorescein, doctors may use lissamine green staining, another type of dye that helps assess the overall health of the eye’s surface. While fluorescein shows areas where cells are completely missing, lissamine green highlights damaged or dying cells that are still present but not functioning properly. Together, these two staining methods provide a comprehensive picture of the extent of damage to the corneal surface.^[4]

Assessment of the Limbus and Stem Cells

A critical part of diagnosing persistent defects involves examining the limbus, which is the border area between the clear cornea and the white part of the eye. This region contains special stem cells called limbal stem cells that are responsible for generating new corneal surface cells. The doctor will look for the Palisades of Vogt, which are small vertical ridges at the limbus that indicate healthy stem cell populations.^[4]

When examining this area, doctors look for signs of stem cell deficiency, such as blood vessels growing into areas where they shouldn’t be, scarring, or absence of the normal limbal structures. They also check for Salzmann’s nodules, which are small bumps that can develop on the cornea and interfere with healing. Understanding the health of these stem cells is essential because without adequate stem cell function, the cornea cannot produce enough new cells to cover defects.^[4]

Examination for Underlying Conditions

Since persistent epithelial defects often result from underlying conditions, the diagnostic process includes checking for these contributing factors. The doctor will examine both eyes, even if only one is symptomatic, because findings in the unaffected eye can reveal systemic problems. They will look for signs of basement membrane abnormalities, check for corneal swelling related to conditions like Fuchs’ dystrophy (a condition where the inner layer of the cornea doesn’t function properly), and assess whether calcium deposits called band keratopathy are present on the cornea.^[4]

The examination includes checking the inside of the eye with specialized instruments. The doctor will look into the anterior chamber—the space between the cornea and the colored iris—to check for inflammatory cells or cloudiness that might indicate infection or inflammation. They will also assess whether any infiltrates (collections of inflammatory cells) or haze are present in the cornea itself, as these can be warning signs of concurrent infection that requires different treatment.^[10]

Dilated Eye Examination

A comprehensive diagnostic evaluation often includes dilating the pupils to examine the back of the eye. This is particularly important for patients with diabetes, as the presence of diabetic retinopathy (damage to blood vessels in the retina) suggests that diabetes may also be affecting corneal healing. The dilated exam can reveal other systemic conditions that manifest in the eye and contribute to poor wound healing.^[4]

Tear Film and Ocular Surface Assessment

Evaluating tear production and quality is essential when diagnosing persistent defects, as chronic dry eye significantly impairs corneal healing. Doctors may assess the tear film’s stability, measure tear production volume, and examine the oil-producing glands in the eyelids called meibomian glands. Dysfunction of these glands can lead to rapid tear evaporation and chronic dry eye that prevents epithelial healing.^[6]

Imaging and Advanced Diagnostic Tools

In some cases, specialized imaging techniques provide additional diagnostic information. In vivo confocal microscopy allows doctors to see the cellular structure of the cornea at a microscopic level without taking a biopsy. This technology can reveal changes in the cells and nerve fibers that aren’t visible with standard examination methods. Infrared photography of the meibomian glands can show whether these oil-producing structures have deteriorated, which helps explain tear film problems contributing to the defect.^[6]

Measurement of the lipid layer thickness (the oily layer of the tear film) provides objective data about tear film quality. A thin lipid layer indicates poor meibomian gland function, which leads to rapid tear evaporation and a hostile environment for corneal healing. These measurements, combined with clinical findings, help doctors understand the complete picture of factors preventing healing.^[6]

Documentation and Monitoring

Proper diagnosis involves not just identifying the defect at a single point in time but also documenting its characteristics for comparison at future visits. Doctors typically measure the defect’s dimensions, note its exact location on the cornea, describe its shape, and photograph it using both regular white light and blue light with fluorescein staining. This documentation allows them to determine whether the defect is healing, staying the same, or getting worse with treatment.^[10]

Frequent monitoring is typically required during the treatment period. In the early stages of treatment, patients may need to be seen daily or every few days so the doctor can assess whether the chosen treatment approach is working. This close follow-up is essential because persistent defects that don’t respond to initial treatment may need more aggressive interventions, and delays in adjusting the treatment plan can lead to complications.^[10]

Diagnostics for Clinical Trial Qualification

When patients with persistent corneal epithelial defects are being considered for enrollment in clinical trials, they undergo additional standardized diagnostic tests beyond routine clinical evaluation. These tests serve as criteria to determine whether a patient’s condition meets the specific requirements for participating in research studies testing new treatments.^[2]

Clinical trials typically require precise documentation of the defect’s size, measured in specific units such as square millimeters. The measurement must be performed using standardized techniques to ensure consistency across different patients and study sites. Fluorescein staining with calibrated photography is the standard method used to obtain these measurements. Some trials may require that the defect be present for a minimum duration—often at least two weeks—despite receiving standard supportive treatment, to confirm that it truly qualifies as persistent.^[1]

Trials may also establish specific inclusion criteria related to the underlying cause of the persistent defect. For example, a study might specifically recruit patients whose defects resulted from neurotrophic keratopathy (nerve damage affecting the cornea) or from surgical complications, while excluding those with active infections or certain corneal dystrophies. This means that diagnostic testing must not only confirm the presence of the defect but also identify or rule out specific underlying conditions.^[2]

Additional diagnostic requirements for trial qualification often include assessment of corneal sensation using specialized instruments that can quantify the degree of nerve function. Measurements of tear production, such as the Schirmer test (which uses paper strips to measure tear volume), may be required to document the severity of any accompanying dry eye disease. Visual acuity testing using standardized eye charts provides baseline measurements that can be compared after treatment to determine whether the therapy improved vision.^[6]

Some clinical trials require advanced imaging as part of the qualification process. Confocal microscopy might be used to document the cellular characteristics of the defect and surrounding tissue at the microscopic level. Anterior segment optical coherence tomography, a non-invasive imaging technique that creates cross-sectional images of the front of the eye, may be used to assess the depth of corneal involvement and track changes over time.^[6]

Laboratory testing may be part of trial qualification, particularly tests to rule out conditions that would exclude someone from participation. Blood tests might be required to check for uncontrolled diabetes, autoimmune markers, or other systemic conditions that could affect safety or outcomes. Microbiological cultures from the eye may be necessary to confirm that no active infection is present, as most trials exclude patients with infected corneal defects.^[4]

Trial protocols often specify exactly which diagnostic tests must be performed at baseline (before treatment starts) and at regular intervals throughout the study. This standardization ensures that all participants are assessed using the same methods, making it possible to compare results across individuals and determine whether the experimental treatment is effective. The frequency of these diagnostic assessments is typically more intensive than routine clinical care, often requiring weekly or even more frequent examinations during the active treatment phase.^[2]